Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab

OBJECTIVES: Several concerns regard the immunogenicity of SARS-CoV-2 vaccines in people with multiple sclerosis (pwMS), since the majority of them is treated with immunomodulating/immunosuppressive disease modifying therapies. Here we report the first data on the humoral response to mRNA SARS-CoV-2...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neurol Sci
Main Authors: Gallo, Antonio, Capuano, Rocco, Donnarumma, Giovanna, Bisecco, Alvino, Grimaldi, Elena, Conte, Miriana, d’Ambrosio, Alessandro, Coppola, Nicola, Galdiero, Massimiliano, Tedeschi, Gioacchino
Format: Artigo
Jezik:Inglês
Izdano: Springer International Publishing 2021
Teme:
Covid-19
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8203306/
https://ncbi.nlm.nih.gov/pubmed/34128150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10072-021-05397-7
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki